Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
This syndrome is characterized by multiple doughnut-shaped hyperostotic or osteosclerotic lesions of the calvaria.
Features include rarely findings: Severe short stature, Femoral bowing, Motor delay, and Platyspondyly and others. 12 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 5 | Femoral bowing, Sideways curvature of the spine (scoliosis), Weak and brittle bones (osteoporosis) |
SGMS2 function has not been fully characterized.
Calvarial doughnut lesions-bone fragility syndrome is associated with mutations in the SGMS2 gene on chromosome 4.
Genetic testing for SGMS2 is available. Testing is considered confirmatory for diagnosis.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for calvarial doughnut lesions-bone fragility syndrome.
20 publications have been identified in PubMed for calvarial doughnut lesions-bone fragility syndrome. Research spans Basic Science / Preclinical (47%), Review / Meta-Analysis (21%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 9 | 47% |
Data assembled from 6 of 12 sources · Last updated Oct 4, 2026, 6:18 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Growth and development
1 |
Severe short stature |
Lab test results | 1 | Elevated circulating alkaline phosphatase concentration |
Ears | 1 | Mixed hearing impairment |
Research summaries
4 |
21% |
Patient case studies | 3 | 16% |
Disease patterns and progression | 2 | 11% |
New treatment approaches | 1 | 5% |
Qvist A (2026). [PMID: 42079169](https://pubmed.ncbi.nlm.nih.gov/42079169/). *bioRxiv*. [Basic Science / Preclinical]
Woody C (2026). [PMID: 42027587](https://pubmed.ncbi.nlm.nih.gov/42027587/). *JCEM Case Rep*. [Case Report / Case Series]
Lorenz SM (2026). [PMID: 41349546](https://pubmed.ncbi.nlm.nih.gov/41349546/). *Cell*. [Basic Science / Preclinical]
Dong L (2026). [PMID: 41263626](https://pubmed.ncbi.nlm.nih.gov/41263626/). *Clinical genetics*. [Epidemiology / Natural History]
Pihlström S (2025). [PMID: 40978119](https://pubmed.ncbi.nlm.nih.gov/40978119/). *JBMR plus*. [Basic Science / Preclinical]
Schmidt RE (2025). [PMID: 40246852](https://pubmed.ncbi.nlm.nih.gov/40246852/). *NPJ genomic medicine*. [Epidemiology / Natural History]
Dubot P (2025). [PMID: 38706107](https://pubmed.ncbi.nlm.nih.gov/38706107/). *Journal of inherited metabolic disease*. [Review / Meta-Analysis]
Määttä K (2025). [PMID: 41143154](https://pubmed.ncbi.nlm.nih.gov/41143154/). *JBMR plus*. [Basic Science / Preclinical]
Wang H (2025). [PMID: 41225599](https://pubmed.ncbi.nlm.nih.gov/41225599/). *Orphanet journal of rare diseases*. [Gene Therapy / Novel Therapeutics]
Güneş N (2025). [PMID: 39825918](https://pubmed.ncbi.nlm.nih.gov/39825918/). *Pediatric radiology*. [Basic Science / Preclinical]